Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses
暂无分享,去创建一个
R. Greil | B. Melichar | M. Inbar | I. Láng | R. Anghel | B. Kaufman | T. Brodowicz | S. Špánik | L. Petruzelka | C. Zielinski | T. Pieńkowski | D. Messinger | A. Eniu | K. Koynov | S. Stemmer | D. Vrbanec | Z. Kahán | S. Bešlija | S. Ahlers | L. Petruželka
[1] D. Miles,et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] R. Greil,et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] X. Pivot,et al. A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial. , 2013 .
[4] R. Greil,et al. Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT. , 2013 .
[5] R. Greil,et al. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. , 2013, The Lancet. Oncology.
[6] E. Winer,et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC). , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] T. Buchholz,et al. The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy , 2012, Cancer.
[8] V. Valero,et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial , 2012, Breast Cancer Research and Treatment.
[9] Tanja Fehm,et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. , 2012, The New England journal of medicine.
[10] K Miller,et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Xian Zhou,et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Mark Yoffe,et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.
[13] T. Fehm,et al. Central European Cooperative Oncology Group , 2010, Breast Care.
[14] Arlene Chan,et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Miles,et al. Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer (MBC). , 2009 .
[16] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.